Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model

Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model

Abstract A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one a...

Full description

Bibliographic Details
Main Author: Ingrid W. Caras
Format: Article
Language:English
Published: Wiley 2020-08-01
Series:Stem Cells Translational Medicine
Subjects:
cancer stem cells
clinical trials
drug target
leukemia
immunotherapy
Online Access:https://doi.org/10.1002/sctm.19-0424
id doaj-f1940fa8be4941eda673639b7366c581
record_format Article
spelling doaj-f1940fa8be4941eda673639b7366c5812020-11-25T03:28:18ZengWileyStem Cells Translational Medicine2157-65642157-65802020-08-019882182610.1002/sctm.19-0424Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell modelIngrid W. Caras0California Institute for Regenerative Medicine Oakland California USAAbstract A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody‐mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model.https://doi.org/10.1002/sctm.19-0424cancer stem cellsclinical trialsdrug targetleukemiaimmunotherapy
collection DOAJ
language English
format Article
sources DOAJ
author Ingrid W. Caras
spellingShingle Ingrid W. Caras
Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
Stem Cells Translational Medicine
cancer stem cells
clinical trials
drug target
leukemia
immunotherapy
author_facet Ingrid W. Caras
author_sort Ingrid W. Caras
title Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_short Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_full Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_fullStr Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_full_unstemmed Two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
title_sort two cancer stem cell‐targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model
publisher Wiley
series Stem Cells Translational Medicine
issn 2157-6564
2157-6580
publishDate 2020-08-01
description Abstract A key implication of the cancer stem cell model is that for a cancer therapy to be curative, it is imperative to eliminate the cancer stem cells (CSCs) that drive tumor progression. The California Institute for Regenerative Medicine is supporting two novel approaches that target CSCs, one an antibody‐mediated immunotherapy targeting CD47 and the other an antibody targeting ROR1. This article summarizes the evidence that CSCs are targeted and discusses the results of early clinical trials within the context of the CSC model.
topic cancer stem cells
clinical trials
drug target
leukemia
immunotherapy
url https://doi.org/10.1002/sctm.19-0424
work_keys_str_mv AT ingridwcaras twocancerstemcelltargetedtherapiesinclinicaltrialsasviewedfromthestandpointofthecancerstemcellmodel
_version_ 1724585054182572032

Similar Items